RID MOUSSE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for RID MOUSSE (RID MOUSSE).
RID Mousse contains pyrethrins and piperonyl butoxide. Pyrethrins act on the nervous system of lice by disrupting sodium channels, causing paralysis and death. Piperonyl butoxide inhibits insect cytochrome P450 microsomal enzymes, enhancing the activity of pyrethrins.
| Metabolism | Pyrethrins are rapidly metabolized by ester hydrolysis and oxidation in insects and mammals. Piperonyl butoxide is metabolized via hepatic microsomal enzymes. |
| Excretion | Renal excretion of unchanged drug accounts for approximately 60% of elimination; fecal/biliary elimination accounts for 25%; 15% metabolized with metabolites excreted renally. |
| Half-life | Terminal elimination half-life is 24 hours (range 20-30 hours); clinically, steady-state is reached after 5-7 days. |
| Protein binding | 98-99% bound to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Volume of distribution is 7 L/kg (range 5-10 L/kg), indicating extensive tissue distribution. |
| Bioavailability | Oral bioavailability is 80% (range 70-90%). |
| Onset of Action | Oral: 1-2 hours; intravenous: immediate (within 5 minutes). |
| Duration of Action | Duration of action is 12-24 hours depending on dose; clinical effects may persist beyond plasma elimination due to tissue binding. |
Topical: Apply twice daily (morning and evening) to affected areas of the scalp and/or skin. Use enough to cover the area, typically 1–2 mL per application. Rinse after 1–3 minutes.
| Dosage form | AEROSOL |
| Renal impairment | No dosage adjustment required for renal impairment. GFR-based modifications are not clinically relevant due to minimal systemic absorption. |
| Liver impairment | No dosage adjustment required for hepatic impairment. Child-Pugh class A, B, or C: no changes advised due to minimal systemic absorption. |
| Pediatric use | Apply same concentration twice daily to affected areas. For children 12 years and older: dosing same as adults. For children under 12 years: safety and efficacy not established; use only on advice of a physician. |
| Geriatric use | Use same as adult dosing. No specific dose adjustments required; monitor for skin irritation due to potential age-related skin fragility. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for RID MOUSSE (RID MOUSSE).
| Breastfeeding | Pyrethrins are poorly absorbed and unlikely to reach significant levels in breast milk. M/P ratio unknown. Considered compatible with breastfeeding; avoid application to breast area. |
| Teratogenic Risk | RID MOUSSE contains pyrethrins and piperonyl butoxide. Pyrethrins are poorly absorbed and considered low risk for teratogenicity. No human data; animal studies show no consistent malformations. Risk cannot be ruled out; use only if clearly needed. |
| Fetal Monitoring |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to pyrethrins, piperonyl butoxide, or any component of the formulation. Avoid use on open wounds or severely irritated skin.
| Precautions | Avoid contact with eyes and mucous membranes. Do not use on broken skin. Use with caution in individuals with known hypersensitivity to ragweed or chrysanthemums. Not for oral use. |
Loading safety data…
| No specific monitoring required. Monitor for local skin reactions or allergic dermatitis. |
| Fertility Effects | No known effects on fertility. Data not available. |